Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Audience
Display Only
Showing 834 Results
IVI's Jennifer Bright on Value Assessment and Transparency
In an interview, Innovation and Value Initiative Executive Director Jennifer Bright discusses how her organization has been advancing value assessment practice and the key priorities to make the…
It’s Time to Talk About COVID-19 Prices: Webinar Recap
A summary with video clips from the robust discussion about the societal value and pricing of potential COVID-19 treatments and incentives for current and post-pandemic medical innovation.
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
NPC Weighs in on NQF’s Draft Report on Patient-Reported Outcomes
The National Pharmaceutical Council (NPC) submitted comments to the National Quality Forum (NQF) regarding the Patient-Reported Outcomes: Best Practices on Selection and Data Collection draft…
Ensuring Care for Vulnerable Populations
NPC President and CEO Dan Leonard discusses how the COVID-19 pandemic has highlighted the persistence of barriers that hamper access to health care for many, especially those in vulnerable…
Addressing Low-Value Care in the Time of COVID-19
The COVID-19 pandemic has had an enormous economic impact that is being felt across our communities, businesses and the overall health care system. It has placed a larger spotlight on the challenges…
NPC Comments on CMS Best Price and Barriers to Value-Based Arrangements
NPC outlines how Medicaid Best Price poses a barrier to implementing value-based arrangements and hinders innovation in payment and delivery systems, which can make it difficult for patients to…
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
A Path of Her Own: Salama Freed, 2020-22 NPC/Duke-Margolis Health Policy Fellow
Salama Freed, PhD, has always wanted to learn about the inner-world of health policy – who shapes it, what drives it and how it gets done. She believes that her path to this experience is through the…
Strategies to Optimize Medication Use
The Accountable Care Learning Collaborative (ACLC) hosted a webinar to discuss how value-minded organizations are integrating strategies to optimize medication use to lower costs and improve patient…
Accumulating Barriers to Care: Double Jeopardy for US Patients
In a column for PharmaBoardroom, Dan Leonard, National Pharmaceutical Council President and CEO, Kimberly Westrich, Vice President of Health Services Research, and Brian Sils, Senior Research…
Sustainable Solutions for Patients’ Sake
Blasine Penkowski, Chair of NPC's Board of Directors, proposes some guiding principles on how we can move toward a post-COVID world and build a more resilient system where patients have the care they…
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
CMS Proposes Changes to Medicaid Best Price
CMS announced a proposal to lift some Medicaid best price restrictions, making it easier for commercial health insurers to enter into value-based payment arrangements with biopharmaceutical…
Do Patient Preferences Align with Value Frameworks? A Discrete-Choice Experiment of Patients with Breast Cancer
The study assessed patient preferences for aspects of breast-cancer treatments to evaluate the usual assumptions in scoring rubrics for value frameworks.
NPC Statement on Racial, Social Injustices and Health Disparities
The recent deaths of George Floyd, Ahmaud Arbery and Breonna Taylor have put a spotlight on the racial and social injustices that are unfortunately pervasive in the United States. The COVID-19…
Evolution of the AMCP Format for Formulary Submissions: Yesterday, Today and Tomorrow
The ongoing development of vaccines and treatments for COVID-19 is raising hopes as the world awaits the return to a normal way of life. But as seen in the past decades in the fight against cancer,…
NPC in Health Affairs: It's Time to Talk COVID-19 Treatment Prices
In an article on the Health Affairs Blog, National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois considers questions about COVID-19 treatments and prices and lays out a roadmap to…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Underestimating the Value of an Intervention – The Case for Including Productivity in Value Assessments and Formulary Design
Research shows that including non-health care costs like productivity in value assessment frameworks can change the value assessment of interventions, impact on coverage decisions and subsequent…